1 – 18 of 18
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The influence of domain permutations of an albumin-binding domain-fused her2-targeting affibody-based drug conjugate on tumor cell proliferation and therapy efficacy
(
- Contribution to journal › Article
- 2020
-
Mark
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
(
- Contribution to journal › Article
-
Mark
Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model
(
- Contribution to journal › Article
-
Mark
HER2-specific pseudomonas exotoxin a pe25 based fusions : Influence of targeting domain on target binding, toxicity, and in vivo biodistribution
(
- Contribution to journal › Article
- 2016
-
Mark
Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules
(
- Contribution to journal › Article
- 2015
-
Mark
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
(
- Contribution to journal › Article
- 2014
-
Mark
Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo
(
- Contribution to journal › Article
-
Mark
Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates
(
- Contribution to journal › Article
-
Mark
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
(
- Contribution to journal › Article
-
Mark
Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde
(
- Contribution to journal › Article
-
Mark
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re
(
- Contribution to journal › Article
-
Mark
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule
(
- Contribution to journal › Article
-
Mark
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment
2014) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(11). p.8-1842(
- Contribution to journal › Article
- 2013
-
Mark
Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules : comparison with (111)In-labeled counterparts
(
- Contribution to journal › Article
-
Mark
Influence of nuclides and chelators on imaging using affibody molecules : comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA
(
- Contribution to journal › Article
-
Mark
[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours
(
- Contribution to journal › Article
-
Mark
HAHAHA, HEHEHE, HIHIHI, or HKHKHK : influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules
(
- Contribution to journal › Article
- 2012
-
Mark
Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules
(
- Contribution to journal › Article